



June 10, 2026

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai – 400001

Scrip code: 524632

Sub: Outcome of the meeting of the Board of Directors held on Wednesday, June 10, 2026.

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015.

Dear Sir/Madam,

With reference to above subject and in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e., Wednesday, June 10, 2026, at 6.00 p.m. and concluded on 6.50 p.m. *inter alia* considered and approved the following:

1. The Board considered and approved the proposal to seek fresh approval of the shareholders by way of a Special Resolution in terms of Regulation 170(2) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, in respect of the preferential issue of 46,43,000 Convertible Equity Warrants originally approved by the shareholders at the Extra-Ordinary General Meeting held on November 01, 2025, for which in-principle approval from BSE Limited was received vide its letter dated January 09, 2026. Since the allotment of the said warrants could not be completed within the period prescribed under Regulation 170(1) of the SEBI ICDR Regulations, fresh approval of the shareholders is required under Regulation 170(2) of the SEBI ICDR Regulations. Accordingly, the issue price of the warrants shall be re-computed in accordance with the applicable provisions of Chapter V of the SEBI ICDR Regulations and the warrants shall be allotted at a price not lower than the higher of (i) ₹34/- per warrant, being the issue price approved by the shareholders at the aforesaid Extra-Ordinary General Meeting, and (ii) the price determined pursuant to such re-computation under the SEBI ICDR Regulations.

CIN : L24231GJ1993PLC019079



SHUKRA PHARMACEUTICALS LTD.

The Detailed disclosure as required under Regulation 30(6) read with Schedule III, Part A, Para A of the SEBI Listing Regulations and the SEBI Circular CIR/CFDICMDI4I2015 dated 9 September 2015 for preferential issue is attached herewith as an **Annexure-A**.

2. The Board noted that the Relevant Date for determination of the issue price in accordance with Chapter V read with Regulation 161 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 shall be **Friday, June 05, 2026**, being the trading day immediately preceding Saturday, June 06, 2026, which falls 30 (thirty) days prior to the date of the Extra-Ordinary General Meeting proposed to be held on July 06, 2026.
3. Approved the Notice convening the Extra-Ordinary General Meeting of the Company to be held on Monday, July 06, 2026 through Video Conferencing/Other Audio-Visual Means.
4. Appointed Ms. Rupal Patel, Practicing Company Secretary, as Scrutinizer for conducting the voting process of the Extra-Ordinary General Meeting in a fair and transparent manner.



The meeting of the Board of Directors commenced at 6:00 P.M. and concluded at 6:50 P.M.

Kindly take the same on your records.

Thanking you,

Yours faithfully,

For, Shukra Pharmaceuticals Limited

Arpita Kabra



Arpita Kabra
Company Secretary
ACS No. A50258

CIN : L24231GJ1993PLC019079



Annexure- A

SN	Particulars	Details
1	Types of Securities proposed to be issued	Convertible equity warrants carrying a right to subscribe 1 (one) Equity Share per warrant.
2	Types of Issuances	Preferential allotment on a private placement basis in accordance with the provisions of the Companies Act, 2013 and the rules made thereunder and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("ICDR Regulations") and other applicable laws.
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (Approximately)	<p>46,43,000 (Forty-Six Lacs Forty Three Thousand) Convertible Equity Warrants (hereinafter referred to as "Warrants") on preferential basis ("Preferential Offer") to the Promoter category as mentioned below ("Warrant Holder"/" Proposed Allottee") for cash consideration at a revised price of Rs.35.56/-, aggregating upto Rs.16,51,05,080/- (Rupees Sixteen Crore Fifty-One Lakhs Five Thousand Eighty Only)</p> <p>The price of the warrants has been determined in accordance with the ICDR Regulations. The preferential issue will be undertaken for cash consideration.</p> <p>In terms of Regulation 170(2) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, fresh approval of the shareholders is being sought and the Company has undertaken a fresh pricing exercise based on the Relevant Date of June 06, 2026. Accordingly, the revised issue/exercise price of each Convertible Equity Warrant has been determined at Rs.35.56 per warrant.</p> <p>An amount equivalent to 25% of the original warrant issue price has already been received from the proposed allottees at the time of allotment of warrants pursuant to the earlier shareholders' approval and in-principle approval granted by BSE Limited.</p> <p>Upon obtaining fresh shareholders' approval under Regulation 170(2) of the SEBI ICDR Regulations, the amount already received shall continue to be appropriated towards the subscription consideration of the warrants. The balance consideration, together with any differential amount arising on account of the revised issue price, shall be payable at the time of exercise of the warrants in accordance with the applicable provisions of the SEBI ICDR Regulations.</p>

CIN : L24231GJ1993PLC019079



SN	Particulars	Details
		The price of the warrants and the number of Equity Shares to be allotted on conversion of warrants shall be subject to appropriate adjustments as permitted under applicable laws.
4	Name of the Investors	As per Schedule -I
5	Post allotment of securities- outcome of the subscription	The equity shares are proposed to be allotted to Promoters. Details of the shareholding of Investors in the Company, prior to and after the proposed Preferential Issue, are as under: <i>As per Schedule – I</i>
6	Issue Price	Rs.35.56/- (Thirty Five Rupees Fifty-Six Paise Only) per warrant
7	Number of Investor	5
8	In case of convertibles — intimation on conversion of securities or on lapse of the tenure of the instrument;	The tenure of the warrants shall not exceed 18 (eighteen) months from the date of allotment. Each warrant shall carry a right to subscribe 1 (one) Equity Share per warrant, which may be exercised in one or more tranches during the period commencing from the date of allotment of warrants until the expiry of 18 (eighteen) months from the date of allotment of the warrants. In the event that, a warrant holder does not exercise the warrants within a period of 18 (Eighteen) months from the date of allotment of such warrants, the unexercised warrants shall lapse and the amount paid by the warrant holders on such Warrants shall stand forfeited by the Company.
9	Any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not Applicable

CIN : L24231GJ1993PLC019079




Schedule – I

Sr. No.	Name of shareholders Category : Promoter	Pre issue shareholding		Addition	Post issue shareholding	
		No. of equity shares held	Percentage (%)	Addition	No. of shares Post capital	Percentage of total holding (post diluted) (%)
1	ANAR JAYESHBHAI PATEL	43,60,000	1.00	5,00,000	48,60,000	1.10
2	DAKSHESH RAMESHCHANDRA SHAH	43,60,000	1.00	5,00,000	48,60,000	1.10
3	ANAR PROJECT PRIVATE LIMITED	8,22,40,000	18.78	12,35,000	8,34,75,000	18.86
4	PARSHVA TEXCHEM INDIA PRIVATE LTD.	7,51,75,600	17.17	12,35,000	7,64,10,600	17.27
5	NAVKAR SURGICAL GUJARAT LIMITED	5,16,00,000	11.78	11,73,000	5,27,73,000	11.93
Total		21,77,35,600	49.73	46,43,000	22,23,78,600	50.25

For, Shukra Pharmaceuticals Limited

Arpita Kabra
Arpita Kabra
Company Secretary
ACS No. A50258



CIN : L24231GJ1993PLC019079